Biomarkers in renal cancer

Virchows Archiv

Volumn 464, Issue 3, 2014, Pages 359-365

  Moch, Holger ^a   Srigley, John ^b   Delahunt, Brett ^c   Montironi, Rodolfo ^d   Egevad, Lars ^e   Tan, Puay Hoon ^f  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^e KAROLINSKA INSTITUTE   (Sweden)

^f SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Biomarker; Grading; Immunohistochemistry; Molecular pathology; RCC; Staging

Indexed keywords

BIOLOGICAL MARKER; CADHERIN; CARBONATE DEHYDRATASE IX; CAVEOLIN 1; CD57 ANTIGEN; CD82 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYTOKERATIN 20; CYTOKERATIN 7; EPITHELIAL CELL ADHESION MOLECULE; HYPOXIA INDUCIBLE FACTOR; MELAN A; MICRORNA; MUCIN 1; PARVALBUMIN; PAZOPANIB; PROTEIN P63; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR PAX2; TRANSCRIPTION FACTOR PAX8; UVOMORULIN; VIMENTIN; WT1 PROTEIN;

ANGIOMYOLIPOMA; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 3P; CHROMOSOME 9P; DIFFERENTIAL DIAGNOSIS; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KIDNEY ADENOMA; KIDNEY CANCER; KIDNEY CARCINOMA; MACROPHAGE; MOLECULAR PATHOLOGY; ONCOCYTOMA; OVERALL SURVIVAL; PANCREATIC NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; REVIEW; SPINDLE CELL CARCINOMA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CLASSIFICATION; TUMOR DIFFERENTIATION; TUMOR NECROSIS; TUMOR SUPPRESSOR GENE;

CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; HUMANS; KIDNEY NEOPLASMS; MUTATION; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84897044085     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-014-1546-1     Document Type: Review

References (63)

1. Srigley JR, Delahunt B, Eble JN et al (2013) The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia. Am J Surg Pathol 37:1469-1489
2. Delahunt B, Egevad L, Montironi R et al (2013) International Society of Urological Pathology (ISUP) consensus conference on renal neoplasia: rationale and organization. Am J Surg Pathol 37:1463-1468
3. Delahunt B, Cheville JC, Martignoni G et al (2013) The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol 37:1490-1504
4. Tan PH, Cheng L, Rioux-Leclercq N et al (2013) Renal tumors: diagnostic and prognostic biomarkers. Am J Surg Pathol 37:1518-1531
5. Eble J, Sauter G, Epstein J et al (2004) Tumours of the kidney, tumours of the urinary system and male genital organs. WHO classification of tumours. IARC, Lyon
6. UICC: TNM Classification of Malignant Tumours (ed 7th), Wiley-Blackwell, 2009
7. UICC (2002) TNM classification of malignant tumours, 6th edn. Wiley, New York
8. Moch H, ArtibaniW, Delahunt B et al (2009) Reassessing the current UICC/AJCC TNM staging for renal cell carcinoma. Eur Urol 56:636-643
9. Trpkov K, Grignon DJ, Bonsib SM et al (2013) Handling and staging of renal cell carcinoma: the International Society of Urological Pathology consensus (ISUP) conference recommendations. Am J Surg Pathol 37:1505-1517
10. Bonsib SM(2005) T2 clear cell renal cell carcinoma is a rare entity: a study of 120 clear cell renal cell carcinomas. J Urol 174:1199-1202, discussion 1202
11. Bonsib SM (2006) Renal lymphatics, and lymphatic involvement in sinus vein invasive (pT3b) clear cell renal cell carcinoma: a study of 40 cases. Mod Pathol 19:746-753
12. Fuhrman S, Lasky L, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6:655-663 (Pubitemid 13234762)
13. Delahunt B (2009) Advances and controversies in grading and staging of renal cell carcinoma. Mod Pathol: Off J U S Can Acad Pathol, Inc 22(2):S24-S36
14. Delahunt B, Sika-Paotonu D, Bethwaite PB et al (2011) Grading of clear cell renal cell carcinoma should be based on nucleolar prominence. Am J Surg Pathol 35:1134-1139
15. Paner GP, Amin MB, Alvarado-Cabrero I et al (2010) A novel tumor grading scheme for chromophobe renal cell carcinoma: prognostic utility and comparison with Fuhrman nuclear grade. Am J Surg Pathol 34:1233-1240
16. Cheville JC, Lohse CM, Sukov WR et al (2012) Chromophobe renal cell carcinoma: the impact of tumor grade on outcome. Am J Surg Pathol 36:851-856
17. Amin MB, Paner GP, Alvarado-Cabrero I et al (2008) Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases. Am J Surg Pathol 32:1822-1834
18. Dannenmann SR, Thielicke J, Stockli M et al (2013) Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma. Oncoimmunology 2:e23562
19. Morra L, Rechsteiner M, Casagrande S et al (2011) Relevance of periostin splice variants in renal cell carcinoma. Am J Pathol 179:1513-1521
20. Sconocchia G, Spagnoli GC, Del Principe D et al (2009) Defective infiltration of natural killer cells in MICA/B-positive renal cell carcinoma involves beta(2)-integrin-mediated interaction. Neoplasia 11:662-671
21. Boysen G, Bausch-Fluck D, Thoma CR et al (2012) Identification and functional characterization of pVHL-dependent cell surface proteins in renal cell carcinoma. Neoplasia 14:535-546
22. Luu VD, Boysen G, Struckmann K et al (2009) Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma. Clin Cancer Res 15:3297-3304
23. Dahinden C, Ingold B, Wild P et al (2010) Mining tissue microarray data to uncover combinations of biomarker expression patterns that improve intermediate staging and grading of clear cell renal cell cancer. Clin Cancer Res: Off J Am Assoc Cancer Res 16:88-98
24. Patard JJ, Pouessel D, Bensalah K et al (2008) Targeted therapy in renal cell carcinoma. World J Urol 26:135-140
25. Skinnider BF, Folpe AL, Hennigar RA et al (2005) Distribution of cytokeratins and vimentin in adult renal neoplasms and normal renal tissue: potential utility of a cytokeratin antibody panel in the differential diagnosis of renal tumors. Am J Surg Pathol 29:747-754 (Pubitemid 40734424)
26. Skinnider BF, Amin MB (2005) An immunohistochemical approach to the differential diagnosis of renal tumors. Semin Diagn Pathol 22:51-68 (Pubitemid 43163179)
27. Zhou M, Yang XJ, Lopez JI et al (2009) Renal tubulocystic carcinoma is closely related to papillary renal cell carcinoma: implications for pathologic classification. Am J Surg Pathol 33:1840-1849
28. Sangoi AR, Ohgami RS, Pai RK et al (2011) PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma. Mod Pathol: Off J U S Can Acad Pathol, Inc 24:412-424
29. Mete O, van der Kwast TH (2011) Epithelioid angiomyolipoma: a morphologically distinct variant that mimics a variety of intra-abdominal neoplasms. Arch Pathol Lab Med 135:665-670
30. Eble JN (1998) Angiomyolipoma of kidney. Semin Diagn Pathol 15:21-40
31. Olgac S, Hutchinson B, Tickoo SK et al (2006) Alpha-methylacyl- CoA racemase as a marker in the differential diagnosis of metanephric adenoma. Mod Pathol: Off J U S Can Acad Pathol, Inc 19:218-224 (Pubitemid 43118371)
32. The Cancer Genome Atlas Network (2013) Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499:43-9
33. Moch H (2013) An overview of renal cell cancer: pathology and genetics. Semin Cancer Biol 23:3-9
34. Shen C, Kaelin WG Jr (2013) The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol 23:18-25
35. Rechsteiner MP, von Teichman A, Nowicka A et al (2011) VHL gene mutations and their effects on hypoxia inducible factor HIFalpha: Identification of potential driver and passenger mutations. Cancer Res 71:5500-5511
36. Genega EM, Ghebremichael M, Najarian R et al (2010) Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade. Am J Clin Pathol 134:873-879
37. Bui MH, Seligson D, Han KR et al (2003) Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: Implications for prognosis and therapy. Clin Cancer Res: Off J Am Assoc Cancer Res 9:802-811 (Pubitemid 36182618)
38. Moch H, Presti JC Jr, Sauter G et al (1996) Genetic aberrations detected by comparative genomic hybridization are associated with clinical outcome in renal cell carcinoma. Cancer Res 56:27-30 (Pubitemid 26010380)
39. Schraml P, Struckmann K, Bednar R et al (2001) CDKNA2A Mutation analysis, protein expression, and deletion mapping of chromosome 9p in conventional clear-cell renal carcinomas: evidence for a second tumor suppressor gene proximal to CDKN2A. Am J Pathol 158:593-601 (Pubitemid 32158620)
40. Varela I, Tarpey P, Raine K et al (2011) Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469:539-542
41. Pawlowski R, Muhl SM, Sulser T et al (2013) Loss of PBRM1 expression is associated with renal cell carcinoma progression. Int J Cancer J Int Cancer 132:E11-E17
42. Xu X, Hou Y, Yin X et al (2012) Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell 148:886-895
43. Gerlinger M, Rowan AJ, Horswell S et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883-892
44. Kovacs G, Fuzesi L, Emanual A et al (1991) Cytogenetics of papillary renal cell tumors. Genes Chromosom Cancer 3:249-255
45. Speicher M, Schoell B, Du Manoir S et al (1994) Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization. Am J Pathol 145:356-364 (Pubitemid 24245836)
46. Argani P, Antonescu CR, Illei PB et al (2001) Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am J Pathol 159:179-192 (Pubitemid 33704203)
47. Argani P, Hawkins A, Griffin CA et al (2001) A distinctive pediatric renal neoplasm characterized by epithelioid morphology, basement membrane production, focal HMB45 immunoreactivity, and t(6;11)(p21.1;q12) chromosome translocation. Am J Pathol 158:2089-2096 (Pubitemid 32545194)
48. Argani P, Lae M, Hutchinson B et al (2005) Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RTPCR, and DNA PCR. Am J Surg Pathol 29:230-240 (Pubitemid 40170642)
49. Green WM, Yonescu R, Morsberger L et al (2013) Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service. Am J Surg Pathol 37:1150-1163
50. Eichelberg C, Junker K, Ljungberg B et al (2009) Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur Urol 55:851-863
51. Algaba F, Akaza H, Lopez-Beltran A et al (2011) Current pathology keys of renal cell carcinoma. Eur Urol 60:634-643
52. Fisher R, Gore M, Larkin J (2013) Current and future systemic treatments for renal cell carcinoma. Semin Cancer Biol 23:38-45
53. Pena C, Lathia C, Shan M et al (2010) Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from Sorafenib phase III treatment approaches in renal cancer global evaluation trial. Clin Cancer Res: Off J Am Assoc Cancer Res 16:4853-4863
54. Tang PA, Vickers MM, Heng DY (2011) Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far. Hematol/Oncol Clin N Am 25:871-891
55. Minner S, Rump D, Tennstedt P et al (2012) Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma. Cancer 118:1268-1275
56. Choueiri TK, Regan MM, Rosenberg JE et al (2010) Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. BJU Int 106:772-778
57. Heinzelmann J, Henning B, Sanjmyatav J et al (2011) Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma. World J Urol 29:367-373
58. Slaby O, Redova M, Poprach A et al (2012) Identification of MicroRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients. Genes Chromosom Cancer 51:707-716
59. Nakada C, Tsukamoto Y, Matsuura K et al (2011) Overexpression of miR-210, a downstream target of HIF1alpha, causes centrosome amplification in renal carcinoma cells. J Pathol 224:280-288
60. Berkers JHMG, Wolter O, Beuselinck P, Schoffski B, Roskams P, Joniau TAD, Van Poppel S, Lerut, E.S.M.: MicroRNA-141 expression in clear cell renal cell carcinoma is linked with Sunitinib response. European Urology, Supplements
61. Redova M, Poprach A, Nekvindova J et al (2012) Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med 10:55
62. Gamez-Pozo A, Anton-Aparicio LM, Bayona C et al (2012) MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients. Neoplasia 14:1144-1152
63. Wu X, Weng L, Li X et al (2012) Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis. PloS One 7:e35661